Jeff Yass’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Jeff Yass’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-162,300	Closed	-$88K	–	10726
2016 Q3	$88K	Sell	162,300 -41,300	-20%	-$18.9K	﹤0.01%	7992
2016 Q2	$118K	Sell	203,600 -41,200	-17%	-$44K	﹤0.01%	7950
2016 Q1	$357K	Sell	244,800 -265,200	-52%	-$523K	﹤0.01%	6983
2015 Q4	$1.63M	Sell	510,000 -763,400	-60%	-$3.67M	﹤0.01%	4451
2015 Q3	$7.96M	Sell	1,273,400 -116,600	-8%	-$1.09M	﹤0.01%	2094
2015 Q2	$13.8M	Buy	1,390,000 +672,600	+94%	+$5.89M	0.01%	1654
2015 Q1	$5.29M	Buy	717,400 +436,400	+155%	+$2.94M	﹤0.01%	2664
2014 Q4	$1.5M	Sell	281,000 -40,300	-13%	-$206K	﹤0.01%	5028
2014 Q3	$1.62M	Sell	321,300 -267,900	-45%	-$1.65M	﹤0.01%	5009
2014 Q2	$3.95M	Buy	589,200 +320,000	+119%	+$2.04M	﹤0.01%	3466
2014 Q1	$1.95M	Buy	269,200 +200,600	+292%	+$1.19M	﹤0.01%	4404
2013 Q4	$259K	Buy	68,600 +33,900	+98%	+$131K	﹤0.01%	7829
2013 Q3	$116K	Buy	+34,700	New	+$121K	﹤0.01%	8033

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

CDH

Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

MBT

Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return

Jeff Yass's NWBO Position: Q4 2016 in Review

Jeff Yass sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 186,083 shares — an estimated $101K sold.

Jeff Yass first reported a position in NWBO in Q4 2013 and held it in 12 quarters. The position peaked at $6.75M in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

Jeff Yass reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
Jeff Yass sold 186,083 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $101K.
Jeff Yass first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 12 quarters.
Jeff Yass's Northwest Biotherapeutics, Inc. Common stock position peaked at $6.75M in Q2 2015.
8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Susquehanna International Group's 13F filing for Q4 2016, filed 14 Feb 2017.